| Identification | Back Directory | [Name]
Inarigivir (ORI-9020, SB-9000) | [CAS]
475650-36-3 | [Synonyms]
SB-40
SB9000
ORI9020
ORI-9020
ORI 9020
Inarigivir
narigivir SB9000
inarigivir SB9000
Inarigivir (ORI-9020
Inarigivir (ORI-9020, SB-9000)
2'-O-Methyl-P-thiouridylyl-(3'→5')-2'-deoxyadenosine
2'-O-Methyl-p-thiouridynyl-(3'->5')-2'-deoksyadenosine
INARIGIVIR; ORI-9020; ORI 9020; ORI9020; SB-40; SB-9000; SB9000; SB-9000 | [Molecular Formula]
C20H26N7O10PS | [MDL Number]
MFCD31727872 | [MOL File]
475650-36-3.mol | [Molecular Weight]
587.5 |
| Chemical Properties | Back Directory | [density ]
1.98±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
2.98±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
2''-O-Methyl-P-thiouridylyl-(3''→5'')-2''-deoxyadenosine, has identified to be the first orally bioavailable dinucleotide prodrugs for further therapeutic development against the hepatitis B virus (HBV). | [in vivo]
Inarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values[1]. | Animal Model: | Mice[1] | | Dosage: | 100 mg/kg. | | Administration: | IP, daily. | | Result: | Significantly reduced viral DNA in the liver and shows anti-HBV activity similar ADV positive control. |
| [storage]
Store at -20°C |
|
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|